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Aims RhoB plays a key role in the pathogenesis of hypoxia-induced pulmonary hypertension. Farnesylated RhoB promotes growth
responses in cancer cells and we investigated whether inhibition of protein farnesylation will have a protective effect.
....................................................................................................................................................................................................
Methods
and results
The analysis of lung tissues from rodent models and pulmonary hypertensive patients showed increased levels of pro-
tein farnesylation. Oral farnesyltransferase inhibitor tipifarnib prevented development of hypoxia-induced pulmonary
hypertension in mice. Tipifarnib reduced hypoxia-induced vascular cell proliferation, increased endothelium-dependent
vasodilatation and reduced vasoconstriction of intrapulmonary arteries without affecting cell viability. Protective effects
of tipifarnib were associated with inhibition of Ras and RhoB, actin depolymerization and increased eNOS expression
in vitro and in vivo. Farnesylated-only RhoB (F-RhoB) increased proliferative responses in cultured pulmonary vascular
cells, mimicking the effects of hypoxia, while both geranylgeranylated-only RhoB (GG-RhoB), and tipifarnib had an inhibi-
tory effect. Label-free proteomics linked F-RhoB with cell survival, activation of cell cycle and mitochondrial biogenesis.
Hypoxia increased and tipifarnib reduced the levels of F-RhoB-regulated proteins in the lung, reinforcing the importance
of RhoB as a signalling mediator. Unlike simvastatin, tipifarnib did not increase the expression levels of Rho proteins.
....................................................................................................................................................................................................
Conclusions Our study demonstrates the importance of protein farnesylation in pulmonary vascular remodelling and provides a
rationale for selective targeting of this pathway in pulmonary hypertension.
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1. Introduction
Pulmonary hypertension (PH) is characterized by increased pulmonary vas-
cular resistance due to pulmonary vasoconstriction and vascular re-
modelling and hypoxia is one of the major underlying causes of the disease.1
Ras family of proteins, including Rho GTPases, are key regulators of actin
dynamics and cell proliferation.2 Activation of RhoA contributes to sus-
tained hypoxic pulmonary vasoconstriction and pulmonary vascular re-
modelling in hypoxia-induced PH and in other forms of PH.3 We have
recently shown that RhoB, a protein homologous to RhoA is required for
hypoxia-induced HIF-1a stabilization, vascular cell proliferation, and migra-
tion in vitro.4 Coordinated activation of RhoA and RhoB maximizes
contractile responses of VSMCs to hypoxia: RhoB induces actin polymeriza-
tion via its interaction with mammalian homolog of Drosophila diaphanous
(mDia), while RhoA and its effector, Rho kinase, increase phosphorylation
of myosin light chain on Ser19, thereby facilitating the formation of con-
tractile actomyosin (stress) fibres.4 RhoB gene deletion attenuates PH in
mice, indicating a unique role of this protein in the disease pathology.4
RhoB is distinguished from other Rho proteins by being either farnesy-
lated (F-RhoB) or geranylgeranylated (GG-RhoB) while other Rho pro-
teins are only geranylgeranylated.5 Lipid modification (isoprenylation) of
Ras proteins is important for their biological activity. Attachment of the
20-carbon chain (geranylgeranylation) or 15-carbon chain (farnesylation)
at the C-terminal CAAX motif enhances their binding to the cell
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membrane, important step for the interaction with signaling effectors.
Isoprenylation is carried out by enzymes geranylgeranyl-transferases
(GGTase-1 and GGTase-2) or farnesyl-transferase (FTase). Biological
activity of RhoB is thought to be determined by its prenylation status.6 In
cancer cells, geranylgeranylation of RhoB induces apoptosis and is
required for RhoB degradation,7 while farnesylation of RhoB is associ-
ated with pro-proliferative effects.6
Protein prenylation can be inhibited by statins, which limit biosynthesis
of the isoprenoid precursor, mevalonate. In spite of the successful out-
comes in preclinical studies, statins are not effective in the treatment of
human PH.8 This disappointing clinical outcome may result from the fact
that statins do not completely inhibit protein farnesylation at safe thera-
peutic doses,9 suggesting that proteins that require farnesylation for their
activity, like RhoB or Ras, may remain functional.
We hypothesized that selective inhibition of protein farnesylation will
have a protective effect in pulmonary hypertension. FTase inhibitors
(FTIs) have undergone extensive clinical testing in various hematologic
malignancies and progeria.10,11 Recent Phase II clinical trials demon-
strated high effectiveness of lonafarnib in reducing viral infection and
treatment of chronic hepatitis delta.12 Orally bioavailable, non-
peptidomimetic FTI tipifarnib has shown promising effects in clinical trials
for the treatment of leukemia13 and cancer.14 The suitability of FTIs in
treatment of PH has not been investigated, though an isolated case study
has demonstrated a substantial improvement of pulmonary artery sys-
tolic pressure in pulmonary hypertensive leukaemic patient treated with
tipifarnib.15
Our study addresses for the first time the effect of farnesyltransferase
inhibition in prevention of chronic hypoxia-induced pulmonary hyper-
tension and in the regulation of pulmonary endothelial function in vitro
and in vivo.
2. Methods
An expanded Methods section is provided in the Supplementary data,
see Supplementary material online.
2.1 Chronic hypoxia-induced pulmonary
hypertension
2.1.1 Normoxia and chronic hypoxia studies in vivo
All studies were conducted in accordance with UK Home Office
Animals (Scientific Procedures) Act 1986 and institutional guidelines
with the Imperial College ethics review board approval. 10–12 weeks
old C57BL male mice (20 g; Charles River, Margate, UK) were either
housed in normal air or were placed in a normobaric hypoxic chamber
(FIO2 10%) for 2 weeks (n = 6–8/group). Mice were treated twice daily
by oral gavage with either vehicle (2% carboxymethylcellulose in PBS) or
tipifarnib (100 mg/kg/body weight).Treatments started one day prior
hypoxia exposure. Development of PH was verified as described previ-
ously.4 At 2 weeks, the animals were weighed and anesthetized
(Hypnorm 0.25 mL/kg; Midazolam 25 mg/kg IP), and right ventricular sys-
tolic pressure (RVSP) was measured in a closed chest via direct cardiac
puncture in the spontaneously breathing, anesthetized animal. A 27G
needle, connected to a blood pressure transducer (MLT0670,
ADInstruments) and to PowerLab Data Acquisition system
(ADInstruments), was introduced within the second intercostal space
proximal to the sternal angle with an inclination of 45 degrees clockwise.
All data were then analysed using LabChart 7 software. The animals
were then euthanized, the hearts were removed, and the individual
ventricular chambers were weighed. Right ventricular hypertrophy was
assessed as the ratio of right ventricle/left ventricleþ septum. The right
lungs were snap-frozen in liquid nitrogen and stored at -80 C for bio-
chemical measurements. The left lungs were fixed by inflation with 10%
formalin, embedded in paraffin, and sectioned for histology. Transverse
lung sections were stained with van Gieson’s elastic method or smooth
muscle-actin antibody (Sigma) and counterstained with Gill’s No. 2
haematoxylin (Sigma, GHS216). Vascular muscularization was defined as
the proportion of vessels (<50mm diameter) with immunoreactivity for
smooth muscle actin (as evidence for muscularization) over the total
number of vessels stained with elastin.
2.2 PAH lung sections for
immunofluorescent staining of farnesylated
proteins
Archived lung tissue sections from patients undergoing transplantation
for PAH and relevant control material was obtained from the Papworth
Hospital Cambridge and Hammersmith Hospital London tissue banks
with local ethics committee approval (REC reference number 2001/
6003 for Hammersmith Hospital and 08/H0304/56þ 5 for Papworth
Hospital) and informed written consent. The investigation conformed to
the principles outlined in the Declaration of Helsinki.
2.3 Immunostaining of lung sections
Lung sections were immunostained using a rabbit anti-farnesyl-proteins
antibody (Milipore, AB4073) and a mouse anti-alpha-smooth muscle
actin antibody (Dako, M0851), and fluorescently-labelled secondary anti-
bodies. Images were taken under the confocal laser scanning fluores-
cence microscope (Leica TCS SP5) and analysed with Image J.
2.4 Cell culture and treatments
Human pulmonary artery endothelial cells (HPAEC; Promocell, C-
12241, lot 7121003.5 and 4091902) and smooth muscle cells
(HPASMCs; Promocell, C-12521, lot 9033101.6) were cultured, as
described in Ref. 4. The cells were used between passages 3–6. The cells
were kept under normoxia or were exposed to hypoxia (2% O2) for 2–
72 h. In experiments involving a short-term (2 h) exposure to hypoxia,
tipifarnib (Selleckchem) was added to the cells 1 h before the hypoxic
exposure at 0.1mmol/L. In experiments involving a more prolonged ex-
posure to hypoxia (24–72 h), tipifarnib was added to the cells at the start
of hypoxic exposure.4
2.4.1 Intracellular calcium levels
HPAECs grown in 96-well optical bottom plates (Costar, 3603) were
left untreated or were treated with 0.1mmol/L tipifarnib for 24 h.
Calcium flux was induced by thrombin (Sigma, T4648, 1 U/mL) or iono-
mycin (Sigma, I3909, 1mmol/L) for 3 min. Intracellular calcium levels
were studied with Fluo4 NW Calcium Assay kit (Invitrogen, F36206), ac-
cording to the manufacturer’s protocol. Images of cells were taken under
the confocal laser scanning fluorescence microscope (Leica TCS SP5)
and the intensity of Fluo4 fluorescence (excitation 494 nm and emission
516 nm) was measured with Image J.
2.5 Isometric wire myography
Myography was performed on pulmonary artery segments isolated from
control C57BL6 mice or mice exposed to chronic hypoxia. Intralobar
pulmonary artery was removed, dissected free of fat and connective tis-
sues and the vessel segments placed in Mulvany wire myographs to
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measure contraction and relaxation responses. Throughout the experi-
ment, tissues were immersed in physiological salt solution (PSS, NaCl
1.18 x 10-1 mol/L, KCl 4.7 x 10-3 M, MgSO4 1.17 x 10
-3 mol/L, CaCl2 2.5
x 10-3 mol/L, KH2PO4 1.0 x 10
-3 mol/L, EDTA 2.7 x 10-5 mol/L, and glu-
cose 5.5 x 10-3 mol/L) at 36 C, bubbled with 95% O2 and 5% CO2. The
tension of the vessel was normalized to a tension equivalent to that gen-
erated at 90% of the diameter of the vessel at 100 mmHg. Changes in ar-
terial tone were recorded via a PowerLab/800 recording unit (ADI
instruments Pty Ltd., Australia), and analysed using Chart 6.0 acquisition
system (ADI instruments). Arteries were exposed to three challenges of
high potassium solution (KPSS; same composition as PSS except that
NaCl is replaced with KCl 1.24 x 10-1 mol/L) followed by a washout
period of 10 min. Concentration response curves to 9,11-dideoxy-
11a,9a epoxymethanoprostaglandin F2a (U46619; 10-9–3.10-7 mol/L)
and phenylephrine (10-8–10-4 mol/L) were performed on each of the
vessels. Dilatory response curves were recorded in pulmonary arteries
pre-contracted with an EC80 concentration of U46619, and vasodilator
responses to either acetylcholine (10-8–10-4 mol/L) or SNP response
curve (10-8–3.10-5 mol/L) were assessed. Force was recorded via a
PowerLab/800 (AD Instruments Ltd., UK) and analysed using Chart 6.0
acquisition system (AD Instruments Ltd., UK).
2.6 Proliferation, metabolic activity, and
apoptosis assays
HPAECs and HPASMCs proliferation was evaluated using bromodeox-
yuridine (BrdU) assay (Millipore), while cell viability and caspase activa-
tion were assessed using the kit ApoTox-GloTM (Promega). Metabolic
activity (NADH/NADPH levels) was measured in CellTiter 96VR
Aqueous One Solution Cell Proliferation Assay System (Promega, USA).
The levels of cleaved caspase 3 in tipifarnib-treated cells and mouse lungs
were analysed by western blotting. Apoptotic DNA fragmentation was
studied with TACS 2 TdT-DAB In Situ Apoptosis Detection Kit
(Trevigen, 4810-30K).
2.7 Endothelial permeability
Endothelial permeability was measured in Transwell assay.4
2.8 Rho GTPases protein expression and
activity
Active (GTP-bound) RhoA, RhoB levels were measured in pulldown
assays.4 Ras GTP-binding was studied with Raf-1–GST fusion construct
encoding residues 51–131 of the human Raf-1 RBD (generously pro-
vided by Johannes L. Bos, Molecular Cancer Research, UMC Utrecht,
The Netherlands).16
2.9 Activity measurement of
farnesyltransferase and
geranylgeranyltransferase
The protocol was adapted from Berndt et al.,17 replacing the FPP/
[H3]GGPP and peptide substrates with non-radioactive FPP/GGPP and
fluorophore-conjugated peptides. The prenylation substrates, nitroben-
zofurazan (NBD)-GCVLS (FTase substrate), and NBD-GCVLL
(GGTase-1 substrate) become strongly fluorescent upon prenylation.
2.10 Globular/filamentous actin
quantification
The ratio of globular (G) actin to filamentous (F) actin was measured
with G/F-actin In vivo Assay Kit (Cytoskeleton, Denver, CO, USA).
2.11 Real-time RT-PCR analysis
First-strand cDNAs were synthesized directly from HPAECs using the
Superscript Cells Direct cDNA Synthesis Kit (Invitrogen) according to
the manufacturer’s protocol. Polymerase chain reactions (PCRs) were
performed using specific primer pairs for NOS3 (Hs01274659_m1) and
GAPDH (Hs02758991_g1), from TaqmanVR .
2.12 RhoB mutant overexpression
Overexpression of AdGFP (adenoviral control), farnesylated-only RhoB
(F-RhoB) and geranylgeranylated-only RhoB (GG-RhoB), was induced
by adenoviral gene transfer.4 The last four C-terminal aminoacids of the
F-RhoB were CLVS. In GG-RhoB, 16 C-terminal residues of RhoB were
replaced by 13 C-terminal residues of RhoA, with the last four residues
CLVL.18 CMV3/zeo HA-F-RhoB and CMV/zeo HA-GG-RhoB were a
kind gift of Professor George Prendergast, Lancaster Avenue,
Wynnewood, PA). The adenoviral vectors for RhoB mutant overexpres-
sion were from Welgen, Worcester, MA, USA).
2.13 Label- free quantitative proteomics
Cells lysates were separated by SDS-PAGE. After in-gel digestion of the
separated proteins, tryptic peptides were analysed by LC-MS/MS. Data
analysis was performed by applying various criteria to ensure certainty in
the assignment of protein identifications and to select those that were
differentially expressed. Functional associations of the identified proteins
were analysed with STRING (Search Tool for the Retrieval of Interacting
Genes/Proteins 10.0) database (http://string-db.org/, 10 January 2017)
and Ingenuity Pathway Analysis version 01-07.
2.14 Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 Software.
Comparisons were carried out with unpaired Student’s t-test or
ANOVA with Dunnett’s, Tukey or Bonferroni post-hoc tests, as appro-
priate. Statistical significance was accepted for P < 0.05. Data are ex-
pressed as means ± SEM.
3. Results
3.1 Tipifarnib prevents development of
chronic hypoxia-induced pulmonary hyper-
tension in mice
Mice exposed to chronic hypoxia for 2 weeks developed pulmonary
hypertension, characterized by an increase in the right ventricular sys-
tolic pressure (RVSP), right ventricular hypertrophy (RVH) and muscula-
rization of small (<50mm diameter) intrapulmonary arteries (Figure 1A–
D). Pulmonary vascular muscularization was accompanied by an increase
in the protein expression of cell proliferation marker PCNA in the lung
(see Supplementary material online, Figure S1).
Following oral treatment with tipifarnib (100 mg/kg, twice daily), the
mice appeared healthy and no treatment-related mortality or significant
weight loss were noted during the experiment (see Supplementary ma
terial online, Figure S2). Twice-daily oral administration of tipifarnib at
300 mg/kg was shown to alleviate symptoms of PH in a leukaemic pa-
tient.15 However, in mice a lower dose of 100 mg/kg twice daily effi-
ciently inhibited growth of H-ras transfected tumours and therefore this
dose was chosen in our investigation.19 Tipifarnib prevented the
hypoxia-induced increase in RVSP and significantly reduced RVH
and pulmonary arterial muscularization in hypoxic mice (Figure 1A–D).
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The effects of tipifarnib were accompanied by a significant reduction in the
lung expression of PCNA (see Supplementary material online, Figure S1).
3.2 Tipifarnib reduces protein farnesylation
in the lung
Hypoxia increased protein farnesylation in the lung, while tipifarnib had
an inhibitory effect (Figure 2A and B). The effectiveness of the selected
dose of tipifarnib was documented by an increase in the levels of unpre-
nylated farnesylation marker protein HDJ2 and reduction in the levels of
farnesylated RhoB and H-Ras in mouse lungs (Figure 2C and D and see
Supplementary material online, Figure S3). The selectiveness of the anti-
body used to visualize farnesylated proteins was verified by western
blotting (see Supplementary material online, Figure S4). To further inves-
tigate, whether protein farnesylation increases in PH lung, we examined
the levels of protein farnesylation in rat lungs with monocrotaline
(MCT)-induced PH and lungs of human patients with severe PAH.
Consistent with the observations in the remodelled mouse lungs, MCT
rat, and human PAH lungs showed increased levels of protein farnesyla-
tion, compared with healthy controls (1.6- and 1.5-fold increase respect-
ively, P < 0.05) (see Supplementary material online, Figures S5 and S6).
Hypoxic mouse lungs did not show changes in protein levels of FTase,
GGTase or the activity of FTase, but the activity of GGTase was signifi-
cantly reduced compared with normoxic controls (Figure 2E and see
Supplementary material online, Figure S7). Reduction in GGTase activity
may potentially enhance protein farnesylation by increasing bioavailabil-
ity of isoprenoid intermediates and/or protein substrates utilized by
FTase.20
3.3 Tipifarnib increases endothelium-
dependent relaxation of pulmonary
arteries
We evaluated the effect of tipifarnib on vascular reactivity of mouse
intrapulmonary arteries. Acute (2h) ex vivo treatment with tipifarnib
decreased contraction of intrapulmonary arteries to high Kþand prosta-
glandin H2 analogue, U46619 and increased acetylcholine-mediated vas-
orelaxation (Figure 3A–C). Tipifarnib-induced increase in vasorelaxation
was prevented by NOS inhibitor L-NAME, indicative of increased endo-
thelial NOS signaling (see Supplementary material online, Figure S8).
Acute tipifarnib slightly reduced SNP-induced vasorelaxation (see
Supplementary material online, Figure S9).
Figure 1 Tipifarnib attenuates development of chronic hypoxia-induced pulmonary hypertension. (A) right ventricular hypertrophy (RVH), (B) Right ven-
tricular systolic pressure (RVSP), (C, D) vessel muscularization in the lungs of normoxic and chronically hypoxic mice treated with vehicle or tipifarnib
(100 mg/kg). In (D) top panel shows smooth muscle actin (SMA) staining in lung sections from hypoxic control lungs and bottom panel shows SMA staining
in lungs from tipifarnib-treated hypoxic mice. Magnified boxed areas illustrate changes in muscularization of small intrapulmonary arteries. In (A–C) values
are means ± SEM of n = 6; *P < 0.05, **P < 0.01, ***P < 0.001 vs. normoxic control; ##P < 0.01, ###P < 0.001 vs. hypoxic control. 1-way ANOVA with Tukey
post-test.
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.Chronic hypoxia induced pulmonary arteries hypercontractility in
response to high Kþand U46619 and decreased vasorelaxation to
acetylcholine (Figure 3A–C). Chronic (2 weeks) treatment with tipifarnib
reduced Kþ- and U46619-induced contractility and significantly
improved acetylcholine-induced vasorelaxation of intrapulmonary
arteries from hypoxic lungs (Figure 3A–C) but had little effect on relax-
ation to SNP (see Supplementary material online, Figure S9). Twenty-
four-hour treatment with tipifarnib did not significantly affect intracellular
calcium levels in the untreated or thrombin-treated HPAECs (see
Supplementary material online, Figure S10).
3.4 Tipifarnib reduces hypoxia-induced
HPAEC and HPASMC proliferation and
inhibits the activities of H-Ras and small
GTPases in vitro and in vivo
Tipifarnib inhibited hypoxia-induced HPAEC and HPASMC proliferation
(Figure 4A and B), without affecting cell viability or apoptosis in vitro or
in vivo (see Supplementary material online, Figure S11). The drug also pre-
vented hypoxia-induced activation of Ras and Rho proteins in the lung,
without altering protein expression (Figure 4C–E and see Supplementary
Figure 2 Tipifarnib reduces protein farnesylation in lungs of hypoxic PH mice. (A) Immunofluorescent images of farnesylated proteins and a-smooth
muscle actin in the lungs of normoxic mice and vehicle- and tipifarnib-treated hypoxic mice, as indicated. Bar = 10mm. (B) Changes in protein farnesylation in
mouse lungs. Values are mean fluorescence intensities ±SEM of n = 6/group; *P < 0.05. 1-way ANOVA with Tukey post-test. (C, D) Representative western
blots showing tipifarnib-induced accumulation of unprenylated (np; upper band) form of farnesylation marker protein, HDJ2 and reduction in the levels of
farnesylated RhoB and H-Ras in the mouse lung. (E) FTase activity and GGTase activity in the lungs of normoxic (clear boxes) and chronically hypoxic mice
(black boxes). Each data point represents a mean± SD of n = 5–6. The Vmax and Km of the curves were compared using the Michaelis–Menten equation fitted
to data points. **P < 0.005, comparison with normoxic controls, for both Vmax and Km.
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material online, Figure S12). In cultured cells, reduction in RhoB activity
was noted at 2 h and RhoA and Ras activity at 24 h of treatment with tipi-
farnib (see Supplementary material online, Figure S13).
3.5 Tipifarnib reduces F-actin levels and
stabilizes eNOS mRNA in pulmonary
endothelial and smooth muscle cells
Rho-induced actin polymerization reduces the stability of eNOS mRNA
and decreases NO production.21 To better understand the mechanism
of vasorelaxing actions of tipifarnib, we studied the effect of the drug on
actin polymerization in cultured HPAECs and HPASMCs.
Tipifarnib reduced the levels of polymerized actin (F-actin) in hypoxic
HPAECs and HPASMCs and prevented the localization of phosphory-
lated myosin light chain (p-MLC) to stress fibres, indicative of reduced
actomyosin contractility (Figure 5A and B and see Supplementary material
online, Figure S14 A and B).
Increase in the levels of unpolymerized, globular (G)-actin correlated
with increased gene and protein expression of eNOS in tipifarnib-
treated HPAECs and mouse lungs (Figure 5A–G).
3.6 Farnesylated RhoB induces an
activated, pro-proliferative cell phenotype
To evaluate the effect of changes in RhoB prenylation on pulmonary
endothelial cell phenotype, we overexpressed farnesylated-only RhoB
(F-RhoB) or geranylgeranylated-only RhoB (GG-RhoB) in HPAECs.
Both mutants induced stress fibre formation and cell rounding in
HPAECs within 10–24 h of overexpression, with F-RhoB having a more
pronounced effect (Figure 6). Differential effects of the two mutants
were more clearly seen at earlier timepoints of mutant overexpression
(6 h), when F-RhoB, but not GG-RhoB significantly increased endothelial
permeability (see Supplementary material online, Figure S15).
F-RhoB also increased metabolic/proliferative activity in HPAECs and
its effects were inhibited by tipifarnib (Figure 6C).
Label-free proteomics analysis showed significantly increased expres-
sion of 60 proteins in cells overexpressing F-RhoB and 16 proteins in
cells overexpressing GG-RhoB (Figure 6B and see Supplementary mater
ial online, Table S1). Pathway analysis linked F-RhoB with activation of
cell growth and biogenesis, while GG-RhoB with cell cycle inhibition and
protein ubiquitination (see Supplementary material online, Tables S1 and
S2). Consistent with the postulated role of RhoB, we observed a signifi-
cant increase in the levels of F-RhoB-regulated proteins, such as afadin
(cell survival, PDGF and Akt signalling, angiogenesis),22,23 heat shock 70
proteins24 and peroxisome proliferator-activated receptor gamma coac-
tivator- related 1(PPRC1; transcription factor of mitochondrial biogen-
esis),25 in hypoxic mouse lungs, while treatment with tipifarnib had an
inhibitory effect (Figure 7).
Consistent with the results of proteomic profiling, F-RhoB also
increased BrdU incorporation in HPAECs and platelet-derived growth
factor-BB (PDGF-BB) -stimulated HPASMCs while GG-RhoB had an in-
hibitory effect (see Supplementary material online, Figure S16).
3.7 Differential effect of Tipifarnib and
simvastatin on protein expression of small
GTPases
Statin treatment carries health risks associated with increased accumula-
tion of unprenylated Ras proteins contributing to their sudden activation
upon drug withdrawal.26 To highlight potential benefits of FTI-based
therapy, we compared changes in protein expressions of RhoA, RhoB,
and Ras in cells treated with tipifarnib and simvastatin. Tipifarnib did not
significantly alter protein expressions of Ras, RhoA or RhoB, in contrast
to simvastatin, which markedly upregulated the expressions of all studied
proteins (see Supplementary material online, Figure S17 A–C). This differ-
ential effect may result from the fact that FTIs selectively inhibit protein
farnesylation, preserving, or even increasing protein geranylgeranylation,
important for the ubiquitination and subsequent degradation of Ras pro-
teins. In support of this hypothesis, we observed that co-incubation of
tipifarnib-treated cells with GGTase-1 inhibitor, GGTI-298 substantially
elevated protein expressions of RhoA and H-Ras to the levels induced
by simvastatin (see Supplementary material online, Figure S17).
Figure 3 Tipifarnib increases endothelium-dependent relaxation of
pulmonary arteries. In (A–C) graphs on the left show reactivity of intra-
pulmonary arteries pretreated for 2 h with 0.1 lmol/L tipifarnib (Acute
treatment), while graphs on the right show reactivity of intrapulmonary
arteries isolated from normoxic, hypoxic and hypoxic tipifarnib-treated
mice (Chronic treatment). (A) Contraction to high potassium solution;
(B) contraction to U44162; (C) relaxant response to acetylcholine.
Values are means ± SEM of n = 4 for acute treatment and n = 8–12 for
chronic treatment. 0% relaxation corresponding to the level of precon-
traction induced by 3 x 10 -6 mol/L U44162. Statistical significance was
determined using a (A) unpaired t-test or (B, C) a two-way ANOVA
with repeated measures and a Bonferroni post-hoc test. *P < 0.05,
**P < 0.01, ***P < 0.001 vs. control; #P < 0.05, ###P < 0.001 vs. hypoxic
control.
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.4. Discussion
In this study, we show that oral administration of non-peptidomimetic
farnesyltransferase inhibitor tipifarnib to chronically hypoxic mice, signifi-
cantly improves eNOS-dependent vasodilatation, reduces pulmonary
vascular remodelling and prevents hypoxia-induced right heart hypertro-
phy. FTIs have shown promise in treatment of vascular pathologies asso-
ciated with atherosclerosis,27 progeria28 and systemic hypertension29
and here we document potential role of FTIs in treatment of pulmonary
hypertension.
Reduction in pulmonary vascular remodelling by tipifarnib may be
attributed, at least in part, to the inhibition of expression and activity of
Ras proteins (Figure 8). Inhibition of Ras farnesylation inhibits neointimal
thickening of coronary artery,30 reduces PDGF-induced VSMC prolifer-
ation and inhibits the actions of Ras effectors such as endothelin-1 (ET-
1), or TGF-b.31 RhoB is a downstream effector of Ras and regulates
intracellular trafficking of EGF and PDGF receptors and kinases src and
Akt, enhancing cell proliferation and survival.32,33,34 Several human and
animal studies have also established the importance of RhoA and its
downstream mediator, ROCK, in pulmonary arterial contractility and
remodelling.34 Interestingly, tipifarnib reduced the activity of RhoA
which, unlike Ras or RhoB, can only be geranylgeranylated. This effect
may result from increased NO/cGMP/PKG-mediated phosphorylation
of RhoA, known to promote arterial vasodilation.35
Tipifarnib decreased pulmonary arterial vasoconstriction to high
Kþand U46619 in a NOS-independent manner. Considering that RhoB
has a short half-life (2 h for RhoB compared to 24–31 h for Ras and
RhoA) and that the acute treatment with tipifarnib decreased RhoB ac-
tivity without affecting RhoA or Ras, this response can be attributed to
the inhibition of RhoB.
Inhibition of Rho signalling can also account for NOS-dependent in-
crease in vasorelaxation seen in pulmonary arteries treated with tipifar-
nib. Rho/Rho kinase inhibitors increase the levels of unpolymerized,
globular (G)-actin, known to stimulate eNOS expression either by
Figure 4 Tipifarnib reduces cell proliferation and small GTPases activity. Proliferation of (A) HPAECs or (B) HPASMCs cultured in media containing 1%
FBS in normoxia or in hypoxia with or without tipifarnib for 72 h (0.1 mmol/L; BrdU assay). Cells in positive controls were stimulated with 10% FBS.
Activities of (C) RhoA, (D) RhoB and (E) Ras were assessed in lungs of mice exposed to normoxia or chronic hypoxia and treated with either vehicle or tipi-
farnib, as indicated. b-actin was used as a normalization control. Data represent mean fold- change ±SEM of n = 5. *P < 0.05, **P < 0.01 vs. normoxic control;
#P < 0.05, ##P < 0.01 vs. hypoxic control. 1-way ANOVA with Tukey post-test.
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binding to the enhancer region of eNOS promoter36 and/or by
stabilizing eNOS mRNA.21 In addition, G-actin can bind to eNOS resi-
dues 326-333 and shift its enzymatic activity from superoxide formation
toward NO production,37 or stimulate eNOS activity via PI3-kinase/Akt-
mediated phosphorylation.38 Further, depolymerization of actin has
been shown to activate eNOS by reducing stiffness of the cell cortex.39
Accordingly, we observed that increased eNOS gene and protein ex-
pression co-incided with actin depolymerization and reduced activities
of RhoA and RhoB. Tipifarnib improved acetylcholine-induced vasore-
laxation of hypoxic intrapulmonary arteries and increased eNOS protein
expression in the lung. Interestingly, total RhoB knockout in mice did not
affect pulmonary vasoreactivity, possibly as a result of a compensatory
increase in RhoA expression,4 not seen in tipifarnib-treated lungs.
Tipifarnib did not alter intracellular Ca2þ levels in the untreated or
thrombin-treated cells, suggesting that modulation of Rho rather than
Ca2þ-calmodulin signalling40 contributed to the vasorelaxing effects of
the drug.
Tipifarnib is the most clinically relevant agent available, with proven
on-target effects in vivo.41 Clinical trials showed that the drug is relatively
well tolerated, and does not significantly affect cardiovascular func-
tion.42,43 It is important to note, that the outcomes of anti-farnesylation
therapies may vary, depending on disease mechanisms, experimental de-
sign, dose and route of drug administration, FTI specificity and the mode
of action. In this study, tipifarnib reduced pulmonary arterial remodelling
and improved endothelium-dependent vasorelaxation in hypoxic mice in
a mechanism involving inhibition of Ras and Rho signaling. However, in a
mouse model of progeria, tipifarnib prevented loss of arterial media by
reducing farnesylation of progerin. Permanent farnesylation of progerin
Figure 5 Tipifarnib depolymerizes actin and increases eNOS expression in HPAECs and mouse lungs. (A) Graph and (B) representative western blot
show changes in globular/filamentous (G/F) actin ratio in HPAECs treated with tipifarnib (0.1 mmol/L) for 2–24 h, as indicated. n = 7–8. (C) eNOS mRNA
and (D, E) eNOS protein expression in cells stimulated with tipifarnib; n = 5–6. (F, G) eNOS protein expression in the lungs of mice exposed to normoxia or
chronic hypoxia and treated with either vehicle or tipifarnib, n = 6. Results are expressed as fold- change of controls; Data represent mean ± SEM *P < 0.05
vs. normoxic control. 1-way ANOVA with Tukey post-test.
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..is thought to destabilize nuclear lamina in arterial VSMCs, making them
susceptible to shear stress-induced damage.28 In another study, one-
daily intravenous administration of structurally unrelated peptidomi-
metic farnesyltraneferase inhibitor, FTI-276 improved cardiac re-
modelling but failed to significantly alter endothelium-dependent
vasorelaxation in spontaneously hypertensive rats.29
Data from our and other laboratories suggest that the equilibrium be-
tween protein farnesylation and geranylgeranylation is important in con-
trol of growth responses in the cardiovascular system.44,45 In particular,
prenylation status of RhoB is likely to play a role. FTI-induced gain-of-
function increase in GG-RhoB inhibits cancer cell proliferation18 and we
have shown that GG-RhoB inhibits PDGF-induced HPASMC prolifer-
ation. In contrast, F-RhoB stimulates cell proliferation and increases
expression of proteins important for cell survival, cell division,
mitochondrial biogenesis, and energy metabolism. Increased expression
of F-RhoB-regulated proteins was also observed in PH mouse lungs, pro-
viding an argument for the role of RhoB farnesylation in lung responses
to chronic hypoxia. Mechanisms inducing differential prenylation of pro-
teins such as RhoB and affecting the activity of prenyltransferases are
poorly understood.46 It is possible that hypoxia-induced increase in pro-
tein farnesylation results from selective inhibition of GGTase activity20
or changes in expression of regulatory proteins.46
Identification of other FTI targets important in the pathogenesis of
PAH, will require further studies. Database searches for potential farne-
sylation targets (proteins terminating in CAAX motifs) identified dozens
of proteins, some of which can potentially be implicated in the pathogen-
esis of PH. These include several bone morphogenetic proteins, trans-
forming growth factor-b precursors, serine/threonine kinase-11, and
Figure 6 Farnesylated RhoB induces stress fibre formation and increases metabolic activity in HPAECs. (A) The effect of 24 h-overexpression of AdF-
RhoB and AdGG-RhoB on the endothelial actin cytoskeleton. The RhoB mutants were HA-tagged and co-expressed with GFP and AdGFP was used as
adenoviral control (Adcontrol). In merged images F-actin is red, HA is blue and GFP is green. Bar = 10 mm. Western blot shows equal RhoB expression levels
in cells infected with Ad F-RhoB and Ad GG-RhoB. (B) Volcano plot illustrates differences in protein expression profile in cells overexpressing GG-RhoB or
F-RhoB. Dots in the upper right hand and the left hand corner represent significantly altered expression, with the enlarged red dots marking proteins that af-
fect cell metabolic activity/biosynthesis. All up- or down- regulated proteins are listed in the, see Supplementary material online, Table S1 and those that are
involved in metabolic activity/biosynthesis are indicated. The broken lines indicate thresholds of 1.5-fold-change and P-value 0.05; n = 5. (C) Changes in the
metabolic activity in cells overexpressing AdGFP, AdF-RhoB and AdGG-RhoB and treated with tipifarnib, as indicated. Values are means ± SEM of n = 5.
**P < 0.001 vs. control, #P < 0.05 comparison, as indicated. 1-way ANOVA with Tukey post-test.
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inositol-1,4,5-trisphosphate 5-phosphatases (I and IV), all of which are
proteins with potential roles in the growth regulation.47
Our study highlights potential therapeutic benefits of selective inhib-
ition of protein farnesylation, as opposed to the use of general prenyla-
tion inhibitors, such as statins. Statins are not effective in inhibiting
protein farnesylation at safe therapeutic doses9 and induce the accumu-
lation of unprenylated, immature forms of Ras proteins that maintain
partial function.7 In contrast to simvastatin, tipifarnib did not increase
protein expressions of Ras or Rho in vitro or in vivo, possibly as a result of
alternative geranylgeranylation, targeting Rho proteins for proteasomal
degradation.7 These effects were reversed by GGTi-995, supporting the
argument that by shifting the balance towards protein geranylgeranyla-
tion, FTIs may exert better control over disease-related increases in Rho
proteins expression and activity than statins.
Preliminary analysis of lung tissues from MCT rats and PAH patients
showed increased protein farnesylation in the remodelled vessels and
the surrounding tissues, suggesting a potential broader significance of this
pathway in the pathogenesis of the disease. Such an assumption may ap-
pear too far-fetched, considering the complexity of vascular pathology in
PAH.48 However, protein farnesylation increases in numerous other
proliferative and inflammatory disorders46,49 and is likely to affect the
function of a variety of cell types in addition to the cell types studied
here. Hypoxia alone or in combination with other vascular stresses
Figure 7 Farnesylated RhoB increases expression of proteins regulating cell survival, activation of cell cycle and mitochondrial biogenesis. (A) Fold-change
in protein levels of afadin, PPRC1 and HSPA6 in HPAECs overexpressing F-RhoB. Bars are means ± SEM, *P < 0.05; **P < 0.01, comparison with adenoviral
controls (Adcontrol); n = 6. Representative western blots are shown beside the graph. (B) Fold-change in protein levels of afadin, PPRC1 and HSPA1 in nor-
moxic mouse lungs (Normoxia), hypoxic mouse lungs (HypoxiaþVehicle) and lungs of hypoxic mice treated with Tipifarnib (HypoxiaþTipifarnib). HSPA6
is not expressed in rodents and therefore the expression of HSPA1, belonging to the same HSP70 family of proteins and regulated by F-RhoB, was analysed.
Values are means ± SEM of n = 6 and the broken line indicates control level. *P < 0.05; **P < 0.01, comparison with normoxic controls. 1-way ANOVA with
Tukey post-test. Representative western blots are shown beside the graph.
Figure 8 A schematic diagram of the proposed signaling pathway.
FTase: farnesyltransferase; ROCK: Rho kinase; mDia: mammalian
homolog of Drosophila diaphanous.
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contributes to PAH pathology1 and RhoB can be activated by numerous
other factors implicated in the pathogenesis of PAH, including tyrosine
kinases TGF-b/bone morphogenetic protein/smad pathway and growth
factors, fibroblast growth factor, epidermal growth factor, and PDGF.3,33
Further studies will need to address the role of FTIs in non-hypoxic
models of PH and provide a detailed comparative analysis of the effects
of FTIs and statins. Potential pro-apoptotic effects of FTIs will also need
to be considered. Tipifarnib can induce apoptosis in malignant cells50 and
the results of studies examining the effects of farnesyltransferase inhib-
ition in normal adult tissues are unclear.51
To summarize, this study provides a molecular rationale for further
exploring the family of farnesyltransferase inhibitors in treatment of pul-
monary hypertension.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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